FDA Continues to Take Stance That it Will Not Issue CBD Rules

The U.S. Food and Drug Administration (FDA) recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of cannabidiol (CBD) and a new regulatory pathway is needed. Specifically, during an April 11, 2024 hearing before the House Oversight and Accountability Committee, FDA Commissioner Califf stated “the use of CBD raises safety concerns, especially with long-term use. Studies have shown evidence of liver toxicity, interactions with certain medications, and possible harm to the male reproductive system. CBD exposure is particularly concerning for children and during pregnancy.”

The Commissioner then reiterated the Agency is willing to work with Congress to create “a new regulatory pathway that would provide access, safeguards and oversight over products containing CBD in ways that existing pathways cannot.” Per Commissioner Califf, a new regulatory scheme is needed that could “encourage better information to inform consumers about their choices.”

Under the Federal Food, Drug, & Cosmetic Act, any substance, including CBD, must meet certain standards to be lawfully marketed as a dietary supplement or food additive. The lack of rules for CBD, which are long overdue, has been a pain point for the industry. With the FDA continuing to take the position that it cannot regulate CBD under current food additive and dietary supplement laws and looking to Congress to take action, CBD’s fate looks as though it will continue to remain in unregulated purgatory. Should the FDA change its stance, promulgation of new rules that explicitly address the Agency’s concerns regarding CBD is likely the swiftest way for the industry to finally have clarity. In light of the recent testimony, however, we do not anticipate the FDA will promulgate new rules to regulate CBD any time soon. The FDA’s continued failure to take any action forces industry stakeholders to operate in a world of regulatory uncertainty, which is harming the CBD industry and its consumers.

福里律师事务所致力于协助您应对监管变革带来的短期与长期影响。我们拥有丰富的资源，助您应对这些挑战以及与业务运营和行业特定问题相关的其他重要法律考量。请联系本文作者、您的福里客户关系合伙人或我们的 医疗保健与生命科学业务部或我们的 医疗保健业务组 团队。